SINO BIOPHARM(01177) 中国经济网·2025-03-19 23:38Group 1 - Gan Li Pharmaceutical Co., Ltd. has received registration approval for its insulin products in Malaysia, marking its first entry into the Malaysian market, and has established partnerships in over 20 countries including India and Pakistan [1] - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has received approval for its enoxaparin sodium injection in Argentina, with its products already approved in over 40 countries [1] - In 2024, China's pharmaceutical exports are showing significant growth, with Western drug formulations exported to 185 countries amounting to 4.017 billion, a 4.58% increase [2] Group 2 - The Chinese biopharmaceutical industry is experiencing robust growth, with increased innovation and recognition in international markets, leading to diverse outbound strategies including partnerships with multinational companies [3] - The export of vaccines from China has seen a recovery in value, with significant contributions from Western drug formulations, indicating a shift towards higher value in the internationalization of the Chinese pharmaceutical industry [4] - There is a growing interest from multinational pharmaceutical companies in acquiring innovative Chinese biopharmaceutical firms, especially those with differentiated technology platforms, as they seek new growth opportunities amid patent expirations [4] Group 3 - The Chinese biopharmaceutical industry faces challenges in internationalization, particularly due to policy changes in the United States, which has been the largest single market for Chinese Western drug formulations [4] - Companies are advised to enhance R&D innovation, explore emerging markets, and improve supply chain management to optimize their international development strategies [5] - Various government policies are being implemented to support the internationalization of the pharmaceutical industry, including measures to stabilize foreign trade and promote high-quality development [6]